Changes call for genetic cholesterol test

A genetic test for inherited high cholesterol may have little point, experts warned today.

It comes after research published in The Lancet says that many people who are diagnosed with Familial Hypercholesterolaemia inherit a combination of small-effect changes in several genes (polygenic) rather than a large-effect mutation in a single gene (monogenic).

Scientists say their findings have implications for most of the national guidelines on family screening for the condition, which recommend that relatives of those diagnosed are tested.

DNA-based cascade (family) screening to identify other relatives with hypercholesterolaemia has been recommended by NICE if there is a good chance of a monogenic inheritance of the disorder, where they have a 50:50 chance of having the condition.

However, 60% of people with clinically suspected hypercholesterolaemia have no identifiable mutation in any of the three genes (LDLR, APOB, or PCSK9) known to cause the condition.

Professor Steve Humphries, British Heart Foundation professor at University College London, said: “We propose that the clinical diagnosis should be restricted to those in whom a mutation can be identified, whereas those with no detected mutation should be given the clinical diagnosis of polygenic hypercholesterolaemia.

“Both groups of patients will need statin therapy, but the cost effectiveness of cascade testing will differ depending on whether or not there is a polygenic or a single mutation cause.”

The inherited high cholesterol condition is one of the most common inherited disorders, affecting about one in 500 people. It causes very high levels of low-density lipoprotein cholesterol (LDL-C) – which is also called “bad cholesterol” – in the blood.

If it is left untreated, people have a five to eight times greater risk of early heart disease.

However, improvements need to be made to identify patients because at least 75% of cases remain undetected, untreated, or improperly treated.

Previous studies have identified many common genetic variants associated with a small increment in LDL-C levels.

Genotyping for 12 of these single nucleotide polymorphisms (SNPs) was carried out on blood samples from 321 mutation-negative UK patients with hypercholesterolaemia, 319 UK patients with a known mutation, and 3,020 healthy individuals (controls) from the UK Whitehall II study.

Each participant was assigned a weighted LDL-C-raising gene score that was based on the number of risk-associated gene copies inherited. The results were validated when the exercise was repeated in a sample of more than 700 patients from Belgium.

The findings showed that clinically suspected, but mutation negative hypercholesterolaemia, was associated with inheritance of a greater than average number of small-effect LDL-C-raising sequence differences.

Talmud P, Shah S, Whittall R et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet February 22, 2013. doi.org/10.1016/S0140-6736(12)62127-8 [abstract]

, ,

Leave a Reply

Your email address will not be published. Required fields are marked *

Search

Categories

Monthly Posts

Our Clients

BSH
Practice Index